Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
32 Type 1 Diabetes Trials near Los Angeles, CA
Power is an online platform that helps thousands of Type 1 Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerInhaled Insulin for Diabetes in Children
Los Angeles, CaliforniaThis trial tests an inhalable insulin called Afrezza, combined with a long-acting insulin, in children and teenagers with diabetes. Afrezza helps lower blood sugar quickly after eating, and the long-acting insulin keeps it stable all day. The study aims to see if this combination is safe and effective.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 17
Sex:All
319 Participants Needed
DREAM Intervention for Type 1 Diabetes
Los Angeles, CaliforniaDiabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control for people with type 1 diabetes (T1D), which keeps them at lower risk for diabetes complications, but many Latinx adolescents, who make up the largest marginalized ethnic group of youth with T1D in California, use these devices less often and have less optimal glucose control compared to White youth. In phase 1 of this project, we worked directly with Latinx youth, their families, and diabetes care team members in California to develop DREAM, Device use Reimagined through Education And Mentorship, a virtual peer group (VPG) intervention that will encourage and support the use of diabetes devices in Latinx adolescents with T1D. The goals for phase 2 (intervention) of this project are to evaluate the feasibility and acceptability of the stakeholder-informed VPG intervention, and evaluate clinical and person-centered outcomes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:13 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Medical, Developmental, Psychiatric Conditions, Others
120 Participants Needed
CGM Academy for Type 1 Diabetes
Los Angeles, CaliforniaThe goal of this randomized clinical trial is to compare the effects of a virtual education curriculum in blood glucose variation of youth with type 1 diabetes wearing continuous glucose monitoring (CGM) device. The main questions the study aims to answer are:
* Do participants undertaking the proposed curriculum present improved glucose variation than participants of standard education?
* Explore relationships between participant's glycemic outcomes with diabetes distress, diabetes family responsibilities, and number of hours of diabetes education.
Participants in the intervention group will:
* receive an interactive workbook with problem-based learning scenarios and video links about CGM and glucose management strategies.
* participate in four in-depth online group sessions with diabetes care and education specialists
* complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.
Participants in the comparison group will:
* receive standard education provided to all patients at CHLA
* complete questionnaires three times: at the time of study enrollment, week 4 and 6 months.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:8 - 18
Sex:All
90 Participants Needed
FAMS-T1D + Digital Resources for Type 1 Diabetes
Los Angeles, CaliforniaThe goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18 - 24
Sex:All
140 Participants Needed
FAMS-T1D Support Program for Type 1 Diabetes
Los Angeles, CaliforniaThis trial tests a program called FAMS-T1D that helps young adults with type 1 diabetes manage their condition. The program includes regular coaching calls, frequent text messages, and optional support from a friend or family member. The goal is to improve blood sugar control and reduce diabetes-related stress by providing consistent advice and encouragement.
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18 - 24
Sex:All
280 Participants Needed
Omnipod Systems for Type 1 Diabetes
Los Angeles, CaliforniaThe goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 diabetes.
Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting.
Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Period 1) then switch to the opposite system for the next 4 weeks (Period 2). Everyone will use the Omnipod 5 SmartAdjust 2.0 System for the last 4-6 weeks (Period 3). During Period 3, participants will have a goal of administering no more than 3 meal or snack boluses per day.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:2 - 70
Sex:All
160 Participants Needed
iHERO Toolkit for Type 1 Diabetes
Los Angeles, CaliforniaThis research study aims to test a financial and health insurance iHERO Toolkit for young adults with type1 diabetes. The iHERO Toolkit was developed over one year with the type 1 diabetes community, The Diabetes Link organization, and experts. Now, the investigators want to understand the impact of the iHERO Toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. The investigators are doing this study because it will help to better understand how to support health insurance and financial stress and improve self-management outcomes in young adults with type 1 diabetes. The investigators want to understand how the iHERO Toolkit helps all young adults with diabetes, but especially those on Medicaid and who are racially or ethnically diverse. The investigators will ask participants to participate at four-time points over one year. For the first time, participants will fill out online enrollment and demographic forms and 9 surveys. The 9 surveys have 8-40 short questions each, estimated to take about 45 minutes. Participants will also be asked to complete a home A1c collection with a University Hospitals team member on Zoom.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 30
Sex:All
Key Eligibility Criteria
Disqualifiers:Cognitive Impairment, Non-English Speakers, Others
192 Participants Needed
Team Clinic Care for Type 1 Diabetes
Los Angeles, CaliforniaTeam Clinic is a new care approach for middle and high school aged patients living with T1D and their families. This study is a 15-month randomized control trial (RCT) that consists of Virtual Team Clinic Care appointments (primarily telemedicine, and in-person as necessary) and Virtual Team Clinic group appointments with a multidisciplinary diabetes care team. Assignment into 1 of 4 intervention groups Team Clinic Care vs. Standard Care which consist of either Virtual Team Clinic Group or no group.
Groups:
1. Standard Care - No Group
2. Standard Care - Virtual Team Clinic Group
3. Team Clinic Care - No Group
4. Team Clinic Care - Virtual Team Clinic Group Virtual Team Clinic group sessions will be facilitated by clinical care team (e.g., Registered Dietician, Social Worker, Registered Nurse, etc.)
* Patients and parents will attend their own online session
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:10 - 17
Sex:All
79 Participants Needed
Del-desiran for Myotonic Dystrophy
Los Angeles, CaliforniaA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:16 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Diabetes, Heart Failure, Others
Must Not Be Taking:Anti-myotonic Medications
150 Participants Needed
AOC 1001 for Myotonic Dystrophy
Los Angeles, CaliforniaThis trial is testing a new medicine called AOC 1001 to see if it is safe and effective for adults with a muscle disease called Myotonic Dystrophy Type 1. The medicine is given through an IV, and researchers want to know if it helps muscles work better.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 66
Sex:All
37 Participants Needed
ZT-01 for Type 1 Diabetes
Los Angeles, CaliforniaThis trial is testing a drug called ZT-01 to help adults with type 1 diabetes who have low blood sugar at night. ZT-01 increases a hormone that raises blood sugar levels. The study will see if ZT-01 reduces nighttime low blood sugar episodes and check its safety.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 2 Diabetes, Kidney Disease, Others
186 Participants Needed
Eversense CGM for Diabetes
Los Angeles, CaliforniaThis study is evaluating whether a continuous glucose monitor may help people with diabetes better manage their blood sugar.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Critically Ill, Dialysis, Pregnant, Others
Must Not Be Taking:Dexamethasone
925 Participants Needed
Tirzepatide for Pediatric Type 2 Diabetes
Los Angeles, CaliforniaThis trial is testing tirzepatide, a medication that helps control blood sugar levels, in children and teenagers with type 2 diabetes. These participants are already taking other diabetes medications like metformin or basal insulin. Tirzepatide works by helping the body use insulin more effectively and reducing sugar production in the liver. Tirzepatide is a new medication being tested for its effectiveness and safety in people with type 2 diabetes.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Age:10 - 18
Sex:All
99 Participants Needed
HDV-Insulin Lispro for Type 1 Diabetes
Pasadena, CaliforniaThe goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 79
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Liver Abnormalities, Drug Abuse, Others
Must Be Taking:Insulin
230 Participants Needed
Tirzepatide vs Dulaglutide for Type 2 Diabetes
Pasadena, CaliforniaThe purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
13299 Participants Needed
Denosumab for Type 1 Diabetes
Duarte, CaliforniaType 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy. However, in the early stages of T1D, some beta cells are still alive and functioning. Treatment to protect the beta cells against injury at this time could slow the progress of disease. Denosumab is an approved treatment for osteoporosis (a disease that thins and weakens the bones), high blood calcium levels, bone cancer, and other bone problems in patients who have cancer. The research team has found that the bone pathway that denosumab works on to treat these bone conditions also has effects on the health of the beta cells. Lab studies suggest that denosumab may protect and/or increase the number of beta cells and improve how well they work. This study will test whether denosumab is safe and improves beta cell function and blood sugar control in people with early T1D.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Vitamin D3 Deficiency, Eating Disorder, Obesity, Others
Must Not Be Taking:Immunosuppressants, Anticonvulsants, Steroids, Others
45 Participants Needed
Gastrin + Islet Transplant for Type 1 Diabetes
Duarte, CaliforniaThis clinical study will evaluate the safety and effectiveness of Gastrin treatment with islet transplantation to help patients with difficult to control type 1 diabetes make insulin again and improve blood sugar control.
This study involves two investigational (experimental) products not yet approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease:
1. Human allogenic islet cells (islet cells from a deceased, unrelated human donor)
2. Gastrin-17 (Gastrin) - a hormone secreted by the gut
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 68
Sex:All
Key Eligibility Criteria
Disqualifiers:Kidney Disease, Cardiovascular Disease, Hypertension, Hyperlipidemia, Others
Must Not Be Taking:Anticoagulants
20 Participants Needed
Insulin Pump System for Type 1 Diabetes
Torrance, CaliforniaDiabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c\>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c \>8.5%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Comorbidities, Cognitive Impairment, Pregnancy, Others
40 Participants Needed
Hybrid Closed Loop System for Type 1 Diabetes
Torrance, CaliforniaThe purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Daily Injections (MDI), Continuous Subcutaneous Insulin Infusion (CSII) or Sensor-Augmented Pump therapy (SAP)
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:2 - 80
Sex:All
280 Participants Needed
VX-880 for Type 1 Diabetes
Duarte, CaliforniaThis trial will test the safety and effectiveness of VX-880 infusion in people with Type 1 diabetes who have trouble sensing low blood sugar and experience severe low blood sugar episodes. The treatment aims to help manage their blood sugar levels better.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Prior Transplants, Cell Therapy, Others
52 Participants Needed
Islet Cell Transplant for Type 1 Diabetes
Duarte, CaliforniaCity of Hope National Medical Center, located in Duarte, CA, is hosting a clinical study on islet cell transplantation, an experimental procedure being evaluated as a treatment for patients with type 1 diabetes. Islet cell transplantation involves taking insulin-producing cells from organ donors and transplanting them into the liver of a patient with diabetes. Once transplanted, the islets produce insulin, which can improve blood sugar control and eliminate the need to inject insulin or use an insulin pump.
Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells. T-cells are special white blood cells that recognize and destroy unwanted things like infections but can also attack transplanted cells and organs. Reducing the number of T-cells at the time of transplant may protect islets and improve long-term transplant success. In previous research studies, islet transplantation has been successful in reducing low blood sugar episodes, improving overall blood sugar control, and in some cases, allowing patients with type 1 diabetes to stop taking insulin.
The purpose of this study is to determine if islet cell transplantation using ATG or alemtuzumab, along with additional medications to prevent the body from rejecting the transplanted cells, is a safe and effective treatment for type 1 diabetes. Study participants may receive up to three islet transplants and will be followed for five years to monitor blood sugar control, islet transplant function, and changes in quality of life.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 68
Sex:All
10 Participants Needed
Tolerogenic Dendritic Cell Vaccine for Type 1 Diabetes
Duarte, CaliforniaThis phase I trial investigates the side effects of PIpepTolDC vaccine in treating patients with type 1 diabetes who use insulin and don't have any other diabetes-related health complications. Type 1 diabetes is an autoimmune disease. This means that the immune system, which usually protects against foreign invaders like bacteria and viruses, attacks the body's insulin-producing betacells in the pancreas (autoimmune response). Overtime, the beta cells are destroyed by the immune system. To stay alive, people with type 1 diabetes must use insulin. PIpepTolDC vaccine is a type of immunotherapy (a treatment that uses a person's own immune system) that works like an allergy shot. The vaccine is made using one's own immune cells (dendritic cells) and a beta cell protein. The vaccine may teach the immune system to stop attacking the beta cells, which may help the beta cells recover and make enough insulin to control blood sugar levels. The vaccine may also help reduce future type 1 diabetes related complications.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:All
6 Participants Needed
Islet Transplantation for Type 1 Diabetes
Duarte, CaliforniaThe purpose of this study is to evaluate the safety and effectiveness of islet cell transplantation alone (ITA) in patients with difficult to control type I diabetes. Difficult to control type 1 diabetes is defined as wide swings in blood glucose that disrupt the patient's life and result in frequent episodes of low blood glucose despite the proper use of standard insulin therapy and frequent blood glucose monitoring.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
17 Participants Needed
Continuous Glucose Monitoring for Diabetes
Canoga Park, CaliforniaThe purpose of this study is to evaluate the effectiveness and safety of the RIGHTEST Continuous Monitoring (CGM) System in adult population with diabetes mellitus.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
150 Participants Needed
Aflibercept for Diabetic Macular Edema
Fullerton, CaliforniaPatients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues. Patients may have improved DME with anti-VEGF therapy and ranibizumab has been found to reduce central macular thickness (CMT) with anti-VEGF therapy following vitrectomy. Those patients still require intravitreal injections but the pharmacokinetics of a vitrectomized eye are different than those eyes that have not undergone vitrectomy. The clearance of protein molecules is quicker in vitrectomized eyes so these patients may be more refractory to standard of care anti-VEGF therapy. In rabbit models, the half-life of both bevacizumab and ranibizumab were reduced by a factor 1.8 and 1.3, respectively, after pars plana vitrectomy. In a study examining intravitreal triamcinolone acetonide in human eyes, the half-life was found to be 18.6 days in non-vitrectomized eyes and 3.2 days in vitrectomized eyes, but there was considerable intrasubject variation. Patients with various disease states, including neovascular age-related macular degeneration (nAMD) have been managed with monthly anti-VEGF therapy successfully after vitrectomy surgery. Another study performed by the DRCR net showed that patients with DME treated with anti-VEGF are not affected in the long term if they had had a previous vitrectomy. High dose aflibercept may improve anatomic and visual outcomes in this patient population. Also, high dose aflibercept may allow for longer treatment intervals in these vitrectomized eyes.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:21+
Sex:All
15 Participants Needed
JAK Inhibitors for Type 1 Diabetes
Orange, CaliforniaThis trial is testing two medications, abrocitinib and ritlecitinib, which aim to reduce immune system activity. The study focuses on people who have been recently diagnosed with Stage 3 Type 1 Diabetes. These medications work by calming the immune system to prevent it from attacking insulin-producing cells in the pancreas.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35
Sex:All
Key Eligibility Criteria
Disqualifiers:Infections, Cancer, Heart Disease, Others
Must Not Be Taking:Immunosuppressants, Biologics, Steroids, Others
78 Participants Needed
Low-Dose ATG for Type 1 Diabetes
Orange, CaliforniaA multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:6 - 34
Sex:All
101 Participants Needed
Tirzepatide for Type 1 Diabetes and Obesity
Santa Clarita, CaliforniaThe main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
905 Participants Needed
Rituximab + Abatacept for Type 1 Diabetes
Orange, CaliforniaThis trial is testing whether a combination of two drugs, rituximab-pvvr followed by abatacept, can better preserve insulin production in people newly diagnosed with Type 1 Diabetes compared to rituximab-pvvr alone. Rituximab-pvvr works by reducing harmful immune cells, while abatacept helps calm the immune system. The goal is to see if this combination can improve insulin production and overall diabetes management.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:8 - 45
Sex:All
Key Eligibility Criteria
Disqualifiers:Immune Deficiency, Chronic Infection, Others
Must Not Be Taking:Non-insulin Glycemic
74 Participants Needed
Finerenone for Chronic Kidney Disease in Type 1 Diabetes
Garden Grove, CaliforniaThis trial is testing finerenone, a drug that helps protect kidneys and hearts, in people with chronic kidney disease and type 1 diabetes. The study aims to see how well finerenone works in slowing down kidney damage. Researchers will also monitor the safety of the drug by tracking any medical issues participants experience. Finerenone has been shown to delay the progression of chronic kidney disease and reduce cardiovascular events in patients with diabetic kidney disease, particularly type 2 diabetes.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
220 Participants Needed
Page 1 of 2+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Type 1 Diabetes clinical trials in Los Angeles, CA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Type 1 Diabetes clinical trials in Los Angeles, CA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Type 1 Diabetes trials in Los Angeles, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Los Angeles, CA for Type 1 Diabetes is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Los Angeles, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Type 1 Diabetes medical study in Los Angeles, CA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Type 1 Diabetes clinical trials in Los Angeles, CA ?
Most recently, we added CGM Academy for Type 1 Diabetes, Tirzepatide for Type 1 Diabetes and Obesity and Omnipod Systems for Type 1 Diabetes to the Power online platform.